Larimar Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is LRMR moving today?
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for LRMR.
LRMR insider activity
Larimar Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for LRMR.
LRMR contract awards, year to date.
Public federal awards linked to this ticker.
LRMR lobbying filings, year to date.
Registered lobbying filings matched to Larimar Therapeutics, Inc. Common Stock.